Polyrizon (PLRZ) announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform. The studies were conducted in collaboration with Prof. Fabio Sonvico’s laboratory, utilizing excised rabbit nasal mucosa as a surrogate for human nasal tissues. The research aimed to characterize two key technological aspects of Polyrizon’s formulation: surface coverage capability and mucoadhesive performance, both essential properties for protection against airborne biological assaults and for effective intranasal therapeutic delivery.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRZ:
- Polyrizon Ltd. Increases Outstanding Shares Following Warrant Exercises
- Polyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant Exercises
- Polyrizon announces initiation of preclinical studies for Benzodiazepines
- Upcoming Stock Splits This Week (May 5 to May 9) – Stay Invested
- Polyrizon Ltd. Announces 1-for-10 Reverse Share Split Effective May 5, 2025
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue